Treatment of SEGAs involves a combination of surgical resection and targeted medical therapy with MTOR inhibitors such as everolimus that inhibits the mTOR pathway which is overactive in TSC and contributes to tumour growth [40, 41]. Here, MTOR is linked to tuberous sclerosis.